Top Analyst Reports for Oracle, Lockheed Martin & Boston Scientific
Friday, July 2, 2021
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Lockheed Martin (LMT), and Boston Scientific (BSX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Oracle have outperformed the Zacks Computer Software industry in the year-to-date period (+24% vs. +19.5%). The Zacks analyst believes that Oracle is benefitting from the ongoing momentum across its cloud business, on the back of strong uptake of Oracle Cloud Infrastructure (OCI) services and Autonomous Database offerings.
Further, healthy adoption of cloud-based applications, comprising NetSuite Enterprise Resource Planning (ERP), Fusion ERP and Fusion Human Capital Management (HCM) bodes well in the long run. However, increased spending on product enhancements amid stiff competition in the cloud market is likely to limit margin expansion, in the near term.
(You can read the full research report on Oracle here >>>)
Lockheed Martin’s shares have gained +11.9% over the last six months against the Zacks Aerospace Defense industry’s gain of +19.3%. The Zacks analyst believes that expansionary U.S. budgetary provisions will boost company’s business.
Further, its F-35 program continues to be a key growth program for the company’s Aeronautics business segments, having delivered 17 production aircraft. Lockheed has a stable liquidity position. However, forced cost reduction initiatives for F-35 program might hamper its operating results in future. Moreover, the company is facing performance issues in some of its products, which in turn may weigh on its results.
(You can read the full research report on Lockheed Martin here >>>)
Shares of Boston Scientific have gained +11.1% in the past three months against the Zacks Medical Products industry’s gain of +2.3%. The Zacks analyst believes that accretive acquisitions and significant progress in the company’s restructuring initiatives buoys optimism.
Further, Boston Scientific is gaining traction in the emerging markets, particularly in the BRIC zone. Meanwhile, the company expects a steady recovery from the pandemic with lesser impact from COVID-19 in the second quarter and more normal procedure levels in second half of 2021. Also, the company’s second-quarter view and the narrowed 2021 guidance are impressive.
(You can read the full research report on Boston Scientific here >>>)
Other noteworthy reports we are featuring today include Regeneron Pharmaceuticals (REGN), Roper Technologies (ROP) and Eni (E).
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Oracle (ORCL) Benefits from Strong Uptake of Cloud Solutions
Robust Demand Aids Lockheed (LMT), F-35 program's Cost Hurts
Procedural Gain Aids Boston Scientific (BSX) amid Pandemic
Featured Reports
Eylea, Dupixent and REGEN-COV Fuel Regeneron's (REGN) Growth
Per the Zacks analyst, Eylea and strong performance from asthma drug Dupixent boost Regeneron.
Network Software Business Aids Roper (ROP), High Debt Hurts
Per the Zacks analyst, strength across Roper's network software and medical product businesses will lend momentum to the company.
Eni (E) Rides on Exploration Campaign in Offshore Indonesia
The Zacks analyst believes that Eni's exploration operations in offshore Indonesia will lead to increased production and boost cash flow.
Business Expansion to Drive O'Reilly (ORLY) Amid Cost Woes
While business expansion efforts through new store openings in profitable regions are likely to aid O'Reilly, rising operating expenses may clip the firm's near-term profits, per the Zacks analyst.
Acquisitions Aids TransDigm (TDG), Rising Debt Levels Hurt
Per the Zacks analyst, TransDigm strengthens its position in proprietary aerospace components' niche markets, through strategic acquisitions.
Republic Services (RSG) Solid Operations Aid Amid High Debt
The Zacks analyst is impressed by Republic Services' operational efficiency effort to shift to compressed natural gas collection vehicles. However, a debt-laden balance sheet remains a concern.
NVR's Banks on Higher Deliveries & Backlog, Cost Woes Stay
Per the Zacks analyst, NVR is likely to gain from robust demand for new homes and a strong order backlog. However, higher land labor and material costs are exerting pressure on the margins.
New Upgrades
HDPE Project, A. Schulman Buyout Aid LyondellBasell (LYB)
According to the Zacks analyst, LyondellBasell will benefit from synergies of the A. Schulman buyout and higher capacity driven by the high-density polyethylene (HDPE) project.
BioMarin (BMRN) Banks on Dwarfism Drug Vosoritide's Approval
The potential approval of Biomarin's key pipeline drug, vosoritide will make it the first and only approved treatment for achondroplasia in the United States, which encourages the Zacks analyst.
Nu Skin (NUS) Benefits From Impressive E-Commerce Operations
Per the Zacks analyst, Nu Skin is gaining on higher online sales amid COVID-19. In its last earnings call, management highlighted that over 90% of the company's revenues come from online transactions.
New Downgrades
Increasing Investments to Counter Stiff Competition Ails AMD
Per the Zacks analyst, increasing expenses on product development amid stiff competition in the traditional PC market and GPU segment is likely to hurt AMD's profitability at least in the near term.
Softness in Travel Retail Unit Ails Brown-Forman (BF.B)
Per the Zacks analyst, Brown-Forman's Travel Retail unit remains affected by the pandemic-led travel bans. Fiscal 2021 sales in this unit, excluding the military channel, fell 48% year over year.
Dull Plasma and Blood Center Franchise Ail Haemonetics (HAE)
The Zacks analyst is worried about Haemonetics sluggish Plasma and Blood Center businesses due to the pandemic-led business disruptions affecting the company's top-line.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roper Technologies, Inc. (ROP) : Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Oracle Corporation (ORCL) : Free Stock Analysis Report
Lockheed Martin Corporation (LMT) : Free Stock Analysis Report
Eni SpA (E) : Free Stock Analysis Report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
